CoChat
Sign Up
Cited by 248

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial

Lewis, James H., Mortensen, Mary Ellen, Zweig, Steven, Fusco, Mary Jean, Medoff, Jeffrey R., Belder, Rene·2007·Hepatology
DOI 10.1002/hep.21848
Open this paper in CoChat — free account

Abstract

The hepatotoxic potential of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in patients with underlying chronic liver disease remains controversial. We performed a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial that compared pravastatin (80 mg) to a placebo administered once daily to hypercholesterolemic subjects greater than 18 years of age with at least a 6-month history of compensated chronic liver disease and with a low-density lipoprotein cholesterol (LDL-C) level greater than or equal to 100 mg/dL and a triglyceride (TG) level lower than 400 mg/dL. The efficacy was determined by the percentage change in LDL-C [along with the total cholesterol (TC), high-density lipoprotein cholesterol, and TG] from the baseline to week 12. The safety was analyzed by the proportion of subjects who developed at least 1 alanine aminotransferase (ALT) value greater than or equal to 2 times the upper limit of normal for those with normal ALT at the baseline or a doubling of the baseline ALT for those with elevated ALT at the baseline during 36 weeks of treatment. A total of 630 subjects were screened, and 326 subjects were randomized; nonalcoholic fatty liver disease was present in 64%, and chronic hepatitis C was present in 23%. In the intent-to-treat population, pravastatin (80 mg/day) significantly lowered the mean LDL-C, TC, and TG values at week 12 and at other times (weeks 4, 8, 24, and 36) in comparison with the placebo. The incidence of subjects who met the primary prespecified ALT event definition was lower in the pravastatin group at all times over the 36 weeks of therapy in comparison with the placebo group, although the difference was not statistically significant. No differences were seen on the basis of the baseline ALT values or among the different liver disease groups. Conclusion: High-dose pravastatin (80 mg/day) administered to hypercholesterolemic subjects with chronic liver disease significantly lowered LDL-C, TC, and TGs in comparison with the placebo and was safe and well tolerated. The concern over an increased potential for statin-induced hepatotoxicity in patients with chronic liver disease appears to be lessened on the basis of these results.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.21848

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 57

  1. Vaughan, 2000, The evolving role of statins in the management of atherosclerosis., J Am Coll Cardiol, 35, 1, 10.1016/S0735-1097(99)00525-2 · DOI
  2. Ho, 2006, Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics., Gastroenterology, 130, 1793, 10.1053/j.gastro.2006.02.034 · DOI
  3. Parra, 2003, Hepatotoxicity of hypolipidemic drugs., Clin Liver Dis, 7, 415, 10.1016/S1089-3261(03)00024-2 · DOI
  4. Kornbrust, 1989, Toxicity of the HMGcoenzyme A reductase inhibitor, lovastatin, to rabbits., J Pharmacol Exp Ther, 248, 498
  5. de Denus, 2004, Statins and liver toxicity: a metaanalysis., Pharmacotherapy, 24, 584, 10.1592/phco.24.6.584.34738 · DOI
  6. Silva, 2006, Statinrelated adverse events: a metaanalysis., Clin Ther, 28, 26, 10.1016/j.clinthera.2006.01.005 · DOI
  7. Pfeffer, 2002, Safety and tolerability of pravastatin in longterm clinical trials: Prospective Pravastatin Pooling (PPP) Project., Circulation, 105, 2341, 10.1161/01.CIR.0000017634.00171.24 · DOI
  8. Tolman, 2000, Defining patient risks from expanded preventive therapies., Am J Cardiol, 85, 15, 10.1016/S0002-9149(00)00946-2 · DOI
  9. Tolman, 2002, The liver and lovastatin., Am J Cardiol, 89, 1374, 10.1016/S0002-9149(02)02355-X · DOI
  10. Farmer, 2000, Comparative tolerability of the HMGCoA reductase inhibitors., Drug Saf, 23, 197, 10.2165/00002018-200023030-00003 · DOI
  11. Clarke, 2006, Atorvastatin associated liver disease., Dig Liver Dis, 38, 772, 10.1016/j.dld.2006.04.013 · DOI
  12. Charles, 2005, Evaluation of cases of severe statinrelated transaminitis within a large health maintenance organization., Am J Med, 118, 618, 10.1016/j.amjmed.2005.02.008 · DOI
  13. Knopp, 1999, Drug treatment of lipid disorders., N Engl J Med, 341, 498, 10.1056/NEJM199908123410707 · DOI
  14. Russo, 2004, Liver transplantation for acute liver failure from drug induced liver injury in the United States., Liver Transpl, 10, 1018, 10.1002/lt.20204 · DOI · Paper page
  15. Baessler, 2005, Failure to achieve recommended LDL cholesterol levels by suboptimal statin therapy relates to elevated cardiac event rates., Int J Cardiol, 101, 293, 10.1016/j.ijcard.2004.03.053 · DOI
  16. Gotto, 2003, Safety and statin therapy: reconsidering the risks and benefits., Arch Intern Med, 163, 657, 10.1001/archinte.163.6.657 · DOI
  17. Gotto, 2003, Risks and benefits of continued aggressive statin therapy., Clin Cardiol, 26, III3, 10.1002/clc.4960261503 · DOI
  18. Talbert, 2006, Safety issues with statins., J Am Pharm Assoc (Wash DC), 46, 479, 10.1331/154434506778073637 · DOI
  19. Gotto, 2006, Statins, cardiovascular disease, and drug safety., Am J Cardiol, 97, S3, 10.1016/j.amjcard.2005.12.005 · DOI
  20. Cohen, 2006, An assessment of statin safety by hepatologists., Am J Cardiol, 97, S77, 10.1016/j.amjcard.2005.12.014 · DOI · Paper page
  21. Chalasani, 2004, Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity., Gastroenterology, 126, 1287, 10.1053/j.gastro.2004.02.015 · DOI · Paper page
  22. Chalasani, 2005, Statins and hepatotoxicity: focus on patients with fatty liver., Hepatology, 41, 690, 10.1002/hep.20671 · DOI
  23. Vuppalanchi, 2005, Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes., Am J Med Sci, 329, 62, 10.1097/00000441-200502000-00002 · DOI · Paper page
  24. Khorashadi, 2006, Incidence of statin hepatotoxicity in patients with hepatitis C., Clin Gastroenterol Hepatol, 4, 902, 10.1016/j.cgh.2006.03.014 · DOI
  25. Gibson, 2005, Experience with statin use in patients with chronic hepatitis C infection., Am J Cardiol, 96, 1278, 10.1016/j.amjcard.2005.06.071 · DOI
  26. Rallidis, 2004, Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study., Atherosclerosis, 174, 193, 10.1016/j.atherosclerosis.2004.01.008 · DOI
  27. Imagawa, 1996, Hyperlipidemia after liver transplantation: natural history and treatment with the hydroxylmethylglutarylcoenzyme A reductase inhibitor pravastatin., Transplantation, 62, 934, 10.1097/00007890-199610150-00011 · DOI
  28. Kurihara, 1993, Experimental use of pravastatin in patients with primary biliary cirrhosis associated with hypercholesterolemia., Clin Ther, 15, 890
  29. Ritzel, 2002, Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers., J Hepatol, 36, 454, 10.1016/S0168-8278(02)00006-5 · DOI · Paper page
  30. McKenney, 2006, Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force., Am J Cardiol, 97, S89, 10.1016/j.amjcard.2006.02.030 · DOI · Paper page
  31. Anfossi, 2004, Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits., Nutr Metab Cardiovasc Dis, 14, 215, 10.1016/S0939-4753(04)80008-5 · DOI
  32. Lewis, 2002, The rational use of potentially hepatotoxic medications in patients with underlying liver disease., Expert Opin Drug Saf, 1, 159, 10.1517/14740338.1.2.159 · DOI
  33. Rosenson, 2003, Results of two clinical trials on the safety and efficacy of pravastatin 80 and 160 mg per day., Am J Cardiol, 91, 878, 10.1016/S0002-9149(03)00026-2 · DOI
  34. 2001, Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III)., JAMA, 285, 2486, 10.1001/jama.285.19.2486 · DOI · Paper page
  35. Lin, 1995, Sample size for therapeutic equivalence based on confidence interval., Drug Inf J, 29, 45, 10.1177/009286159502900107 · DOI
  36. McGovern, 1993, Longterm experience with pravastatin in clinical research trials., Clin Ther, 15, 57
  37. Sacks, 1996, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels., N Eng J Med, 335, 1001, 10.1056/NEJM199610033351401 · DOI · Paper page
  38. Lewis, 2000, Druginduced liver disease., Med Clin North Am, 84, 1275, 10.1016/S0025-7125(05)70287-X · DOI
  39. Maron, 2000, Current perspectives on statins., Circulation, 101, 207, 10.1161/01.CIR.101.2.207 · DOI
  40. Bottorff, 2000, Longterm safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors. The role of metabolismmonograph for physicians., Arch Intern Med, 160, 2273, 10.1001/archinte.160.15.2273 · DOI
  41. Pelli, 2003, Autoimmune hepatitis revealed by atorvastatin., Eur J Gastroenterol Hepatol, 15, 921, 10.1097/00042737-200308000-00014 · DOI
  42. Alla, 2006, Autoimmune hepatitis triggered by statins., J Clin Gastroenterol, 40, 757, 10.1097/00004836-200609000-00018 · DOI
  43. Noel, 2007, Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review., J Eur Acad Dermatol Venereol, 21, 17, 10.1111/j.1468-3083.2006.01838.x · DOI
  44. Graham, 2004, Incidence of hospitalized rhabdomyolysis in patients treated with lipidlowering drugs., JAMA, 292, 2585, 10.1001/jama.292.21.2585 · DOI · Paper page
  45. Nathwani, 2005, Serum alanine aminotransferase in skeletal muscle diseases., Hepatology, 41, 380, 10.1002/hep.20548 · DOI
  46. Russo, 2004, Are patients with elevated liver tests at increased risk of druginduced liver injury?, Gastroenterology, 126, 1477, 10.1053/j.gastro.2004.03.030 · DOI
  47. Lewis, 2006, Hys law, the Rezulin rule, and other predictors of severe druginduced hepatotoxicity: putting riskbenefit into perspective., Pharmacoepidemiol Drug Saf, 15, 221, 10.1002/pds.1209 · DOI
  48. Reuben, 2001, Longterm management of the liver transplant patient: diabetes, hyperlipidemia, and obesity., Liver Transpl, 7, S13, 10.1053/jlts.2001.29167 · DOI
  49. Simonson, 2003, Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment., Eur J Clin Pharmacol, 58, 669, 10.1007/s00228-002-0541-7 · DOI
  50. Chalasani, 2004, Statininduced hepatotoxicity., Gastroenterology, 127, 1278, 10.1053/j.gastro.2004.08.058 · DOI
  51. Browning, 2006, Statins and hepatic steatosis: perspectives from the Dallas Heart Study., Hepatology, 44, 466, 10.1002/hep.21248 · DOI
  52. Santinga, 1994, Efficacy and safety of pravastatin in the longterm treatment of elderly patients with hypercholesteroloemia., Am J Med, 96, 509, 10.1016/0002-9343(94)90090-6 · DOI
  53. Raskin, 1995, Efficacy and safety of pravastatin in the treatment of patients with type I or type II diabetes mellitus and hypercholesterolemia., Am J Med, 99, 362, 10.1016/S0002-9343(99)80182-X · DOI
  54. Guyton, 2006, Benefit versus risk in statin treatment., Am J Cardiol, 97, S95, 10.1016/j.amjcard.2005.12.016 · DOI
  55. Vuppalanchi, 2006, Statins for hyperlipidemia in patients with chronic liver disease. Are they safe?, Clin Gastroenterol Hepatol, 4, 838, 10.1016/j.cgh.2006.04.020 · DOI
  56. Pasternak, 2002, ACCAHANHLBI clinical advisory on the use and safety of statins., J Am Coll Cardiol, 40, 567, 10.1016/S0735-1097(02)02030-2 · DOI
  57. Jacobson, 2006, The safety of aggressive statin therapy: how much can lowdensity lipoprotein cholesterol be lowered?, Mayo Clin Proc, 81, 1225, 10.4065/81.9.1225 · DOI

Cited by

Sorted by citations

Metadata

Authors
Lewis, J. H., Mortensen, M. E., Zweig, S., Fusco, M. J., Medoff, J. R., & Belder, R.
Venue
Hepatology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2007-11
Volume
46
Issue
5
Pages
1453-1463
ISSN
0270-9139
DOI
10.1002/hep.21848
Cited by
248
References
4
Language
en
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 2861 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review